"Real social proyects" teaching methodology: from social responsability to RRI, responsible research and innovación

Este año el grupo pretendío ajustar el método docente de proyecto social real a los requisitos de la emergente disciplina de RRI, mediante proyectos de aprendizaje-servicio con ONGs internacionales y mediante iniciativas profesionales que fomenten la empleabilidad de los estudiantes.This term the educational innovation team pretended to adjust the methodology of real social projects to the emerging discipline of RRI, carrying out learning-cooperation projects in collaboration with international NGOS. Also, the team set up initiatives that foster the employability of university students.Tämän vuosikurssin aikana edukatiivisen innovaation ryhmä on pyrkinyt siirtymään sosiaaliseen vastuun käsitteestä juuri syntymässä olevan RRI, responsible research& innovation filosofian piiriin. Tämä on tapahtunut oppimis-yhteistyö projektien kautta, joita on tehty yhteistyössä kolmannen sektorin kanssa sekä myökin aloittamalla hankkeita jotka voivat parantaa opiskelijoiden työllistettävyysmahdollisuuksia. (en finés)Depto. de Teorías y Análisis de la ComunicaciónFac. de Ciencias de la InformaciónFALSEUCMsubmitte

The application of the RRI perspective in innovation educational: "The teaching method of Real Social Project"

Proyecto de innovación educativa en el que introducimos la perspectiva RRI (Investigación e innovación responsable) en la Universidad Complutense de Madrid. 20 años de aplicación del método, más de 1000 alumnos participantes, 200 ONGs.Educational innovation project in which we introduce the RRI perspective (Responsible Research and Innovation) at the Complutense University of Madrid. 20 years of application of the method, more than 1000 students, 200 NGOs.Depto. de Teorías y Análisis de la ComunicaciónFac. de Ciencias de la InformaciónFALSEUCMsubmitte

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols